MAJLA AGUIAR: Open Payments
NPI 1083379119 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$318 in 15 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $252 · 2025 $318
Food & beverage: $318
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $58 |
| Viatris Specialty LLC | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Astellas Pharma US Inc | 1 | $30 |
| Dexcom, Inc. | 1 | $26 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| Hologic Sales and Service, LLC | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Organon LLC | 1 | $17 |
| Amgen Inc. | 1 | $17 |
Products named: YUPELRI, Wegovy, Veozah, Dexcom G6 Transmitter, AIRSUPRA, LEQVIO, APTIMA, Ozempic.
Industry payments across ID — which companies pay providers there.
